Denmark’s Novo Nordisk Seeking Investment in Iran Market
TEHRAN (Tasnim) – Novo Nordisk, world's largest diabetes drug maker, plans to set up a 70 million euro manufacturing plant in Iran following the conclusion of nuclear talks between Iran and world powers.
“It (building of the plant) signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation," Ole Moelskov Bech, head of Novo Nordisk's Near East unit, said in a statement, Reuters reported on Tuesday.
The Danish multinational pharmaceutical company already has a subsidiary in Iran selling insulin and employing 130 people there.
The new facility will create 160 jobs.
Following the conclusion of nuclear talks between Iran and the Group 5+1 (Russia, China, the US, Britain, France and Germany) on July 14, European business executives and politicians are shuttling to Iran to lay the groundwork for investment and trade.
The comprehensive nuclear deal between Iran and the six powers would terminate all nuclear-related sanctions imposed on Iran after coming into force.
